Nocturnal blood pressure dipping as a marker of endothelial function and subclinical atherosclerosis in pediatric-onset systemic lupus erythematosus.
Ambulatory blood pressure monitoring
Cardiovascular diagnostic techniques
Cardiovascular disease
Pediatric systemic lupus erythematosus
Systemic lupus erythematosus
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
03 06 2020
03 06 2020
Historique:
received:
24
12
2019
accepted:
21
05
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Loss of the normal nocturnal decline in blood pressure (BP), known as non-dipping, is a potential measure of cardiovascular risk identified by ambulatory blood pressure monitoring (ABPM). We sought to determine whether non-dipping is a useful marker of abnormal vascular function and subclinical atherosclerosis in pediatric-onset systemic lupus erythematosus (pSLE). Twenty subjects 9-19 years of age with pSLE underwent ABPM, peripheral endothelial function testing, carotid-femoral pulse wave velocity/analysis for aortic stiffness, and carotid intima-media thickness. We assessed the prevalence of non-dipping and other ABPM abnormalities. Pearson or Spearman rank correlation tests were used to evaluate relationships between nocturnal BP dipping, BP load (% of abnormally elevated BPs over 24-h), and vascular outcome measures. The majority (75%) of subjects had inactive disease, with mean disease duration of 3.2 years (± 2.1). The prevalence of non-dipping was 50%, which occurred even in the absence of nocturnal or daytime hypertension. Reduced diastolic BP dipping was associated with poorer endothelial function (r 0.5, p = 0.04). Intima-media thickness was significantly greater in subjects with non-dipping (mean standard deviation score of 3.0 vs 1.6, p = 0.02). In contrast, higher systolic and diastolic BP load were associated with increased aortic stiffness (ρ 0.6, p = 0.01 and ρ 0.7, p < 0.01, respectively), but not with endothelial function or intima-media thickness. In a pSLE cohort with low disease activity, isolated nocturnal BP non-dipping is prevalent and associated with endothelial dysfunction and atherosclerotic changes. In addition to hypertension assessment, ABPM has a promising role in risk stratification and understanding heterogeneous mechanisms of cardiovascular disease in pSLE.
Sections du résumé
BACKGROUND
Loss of the normal nocturnal decline in blood pressure (BP), known as non-dipping, is a potential measure of cardiovascular risk identified by ambulatory blood pressure monitoring (ABPM). We sought to determine whether non-dipping is a useful marker of abnormal vascular function and subclinical atherosclerosis in pediatric-onset systemic lupus erythematosus (pSLE).
METHODS
Twenty subjects 9-19 years of age with pSLE underwent ABPM, peripheral endothelial function testing, carotid-femoral pulse wave velocity/analysis for aortic stiffness, and carotid intima-media thickness. We assessed the prevalence of non-dipping and other ABPM abnormalities. Pearson or Spearman rank correlation tests were used to evaluate relationships between nocturnal BP dipping, BP load (% of abnormally elevated BPs over 24-h), and vascular outcome measures.
RESULTS
The majority (75%) of subjects had inactive disease, with mean disease duration of 3.2 years (± 2.1). The prevalence of non-dipping was 50%, which occurred even in the absence of nocturnal or daytime hypertension. Reduced diastolic BP dipping was associated with poorer endothelial function (r 0.5, p = 0.04). Intima-media thickness was significantly greater in subjects with non-dipping (mean standard deviation score of 3.0 vs 1.6, p = 0.02). In contrast, higher systolic and diastolic BP load were associated with increased aortic stiffness (ρ 0.6, p = 0.01 and ρ 0.7, p < 0.01, respectively), but not with endothelial function or intima-media thickness.
CONCLUSION
In a pSLE cohort with low disease activity, isolated nocturnal BP non-dipping is prevalent and associated with endothelial dysfunction and atherosclerotic changes. In addition to hypertension assessment, ABPM has a promising role in risk stratification and understanding heterogeneous mechanisms of cardiovascular disease in pSLE.
Identifiants
pubmed: 32493472
doi: 10.1186/s13075-020-02224-w
pii: 10.1186/s13075-020-02224-w
pmc: PMC7268394
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
129Subventions
Organisme : NCATS NIH HHS
ID : UL1TR001878
Pays : United States
Organisme : NHLBI NIH HHS
ID : K01HL125521
Pays : United States
Références
J Hypertens. 2005 Sep;23(9):1707-15
pubmed: 16093916
Lupus. 2017 Sep;26(10):1106-1111
pubmed: 28420072
F1000Res. 2015 Jun 23;4:164
pubmed: 26664705
Arthritis Rheum. 1992 Jun;35(6):630-40
pubmed: 1599520
Pediatrics. 2017 Sep;140(3):
pubmed: 28827377
J Hypertens. 2004 Nov;22(11):2087-93
pubmed: 15480091
Heart. 2009 Sep;95(18):1502-7
pubmed: 19482847
Hypertens Res. 2010 May;33(5):381-5
pubmed: 20203684
Hypertension. 2014 May;63(5):1116-35
pubmed: 24591341
Am Heart J. 2003 Jul;146(1):168-74
pubmed: 12851627
Arthritis Rheum. 2009 May;60(5):1496-507
pubmed: 19404953
Arthritis Care Res (Hoboken). 2010 Aug;62(8):1152-9
pubmed: 20235215
PLoS One. 2014 Jan 23;9(1):e86155
pubmed: 24465931
Hypertension. 2013 Sep;62(3):550-6
pubmed: 23817494
Lipids Health Dis. 2004 Dec 16;3:29
pubmed: 15601478
J Pediatr. 1997 Feb;130(2):178-84
pubmed: 9042117
J Hypertens. 2002 Oct;20(10):1995-2007
pubmed: 12359978
Am J Hypertens. 2015 Dec;28(12):1480-8
pubmed: 25944878
J Rheumatol. 2004 Apr;31(4):713-9
pubmed: 15088296
Hypertension. 2008 Sep;52(3):433-51
pubmed: 18678786
Hypertension. 2008 Jan;51(1):55-61
pubmed: 18039980
Hypertension. 2010 Aug;56(2):217-24
pubmed: 20566959
Arthritis Rheum. 2009 Oct 15;61(10):1396-402
pubmed: 19790130
Am J Hypertens. 2016 May;29(5):647-52
pubmed: 26310663
J Pediatr. 2009 Jun;154(6):901-5
pubmed: 19217124
Biol Blood Marrow Transplant. 2018 Aug;24(8):1678-1684
pubmed: 29704542
Arthritis Care Res (Hoboken). 2014 Aug;66(8):1177-85
pubmed: 24376005
J Hypertens. 2002 Nov;20(11):2183-9
pubmed: 12409956
Hypertension. 2010 Nov;56(5):765-73
pubmed: 20937968
N Engl J Med. 2002 Sep 12;347(11):797-805
pubmed: 12226150
J Immunol. 2017 Sep 15;199(6):1979-1988
pubmed: 28779021
Hypertension. 2016 Apr;67(4):693-700
pubmed: 26902495
Int J Mol Sci. 2014 Jun 25;15(7):11324-49
pubmed: 24968272
J Am Coll Cardiol. 2002 Dec 4;40(11):2039-43
pubmed: 12475467
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Am Heart Assoc. 2015 Nov 13;4(11):
pubmed: 26567372
Arthritis Res Ther. 2011;13(5):R156
pubmed: 21955652
J Hum Hypertens. 2011 Nov;25(11):656-64
pubmed: 21544090
Am J Hypertens. 2003 Jun;16(6):434-8
pubmed: 12799090
Atherosclerosis. 2015 Feb;238(2):380-7
pubmed: 25555270
JAMA. 2004 Jul 21;292(3):331-7
pubmed: 15265847
Ann Rheum Dis. 2016 Sep;75(9):1615-21
pubmed: 26458737
Acta Paediatr. 2014 Feb;103(2):225-30
pubmed: 24148136
J Am Soc Nephrol. 2009 Mar;20(3):629-37
pubmed: 19158356
J Am Coll Cardiol. 2010 Apr 20;55(16):1688-96
pubmed: 20394872
Hypertension. 2006 Jul;48(1):40-4
pubmed: 16735644
Pediatr Nephrol. 2013 Feb;28(2):305-13
pubmed: 23052654
J Hypertens. 2015 Aug;33(8):1666-75
pubmed: 26002843
J Am Coll Cardiol. 2011 Sep 6;58(11):1165-73
pubmed: 21884956
Arthritis Care Res (Hoboken). 2018 Oct;70(10):1478-1487
pubmed: 29316357